Abbott enters its third-quarter report with a credibility test. Three months ago, management argued that the company had turned a corner: comparable sales growth picked up to 4.8% after two sluggish quarters, gross margin hit 58%, and the earnings outlook moved higher. The catch is that full-year comparable sales guidance of 6.5% to 7.5% was reaffirmed, not raised. With the first half running below that range, the second half has to carry real weight. This is the first quarter where that bet gets graded.

Wall Street expects earnings of $1.42 a share on revenue of $12.91 billion. That points to roughly 9% EPS growth and nearly 14% revenue growth from a year ago. The revenue figure is flattered by the addition of Exact Sciences, so the comparable growth rate matters more than the headline number. The EPS estimate sits exactly at the midpoint of management's $1.38 to $1.46 quarterly guidance. The whisper number of $1.44 is only a couple of cents higher, a modest signal that some investors expect the margin story to deliver a small beat. For the full year, the $5.48 consensus sits near the bottom of the raised $5.45 to $5.60 range. Analysts have not fully bought into the upgrade. A clean quarter could pull estimates toward the middle of that range.

Management said four businesses would drive about 80% of the second-half lift, so those are the places to look first. In nutrition, the U.S. pediatric business has become the leader in both WIC and non-WIC channels, and Ensure consumption has been growing at a double-digit pace. Another sequential step up would show that these share gains are lasting. In electrophysiology, growth has been in the low teens, and the Volt 2.0 pulsed field ablation catheter moves to full U.S. release this quarter. That makes the U.S. figure a direct read on whether Abbott can compete in the fastest-moving part of the market. Core lab needs continued strength in U.S. hospital labs and a further narrowing of declines in China. Cancer diagnostics, led by Cologuard, should keep growing in the mid-teens. If all four deliver, the 6.5% to 7.5% target looks achievable. If even one stalls, the math gets uncomfortable.

The weak spots deserve equal attention. Continuous glucose monitoring, once the company's growth engine, slowed to 9.5% last quarter. Management now describes 8% to 9% growth as a plateau until reimbursement expands. The biggest potential catalyst is Medicare coverage for type 2 patients who do not use insulin, which could come this fall. Any update on that decision, along with early international uptake of the dual glucose-ketone LibreDuo sensor, could matter more to the stock than the quarter's diabetes revenue. Rapid and molecular diagnostics fell 8% on a soft respiratory season, and the timing of the next one is largely outside Abbott's control. U.S. mitral structural heart has lost ground to competitors, with recovery pushed to the fourth quarter. Commentary on U.S. procedure volumes will also matter, given investor worries about insurance disenrollment.

Sentiment has shifted noticeably. Going into last quarter, it was solidly bearish. Today it sits slightly on the bullish side. The stock has gained 6.9% since the last report, about 3.5 points better than the S&P 500. Still, it trades near $102, below its 200-day moving average and well under the post-earnings high of $117.34. In other words, the market priced in some of the improvement and then gave a good part of it back. That leaves room for a rebound if the numbers confirm the story, without the stretched expectations that make a stock fragile.

The central question is simple. Does comparable sales growth move clearly above last quarter's 4.8%, while gross margin holds near 58%? If so, the raised earnings outlook looks conservative and the momentum story holds. If growth stays stuck near mid-single digits, a beat driven by margins alone will not be enough. In that case, the reaffirmed sales target starts to look like a promise deferred.